The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer
(ندگان)پدیدآور
Fang, ZhixiongHe, LangqiuJia, HuiHuang, QiushengChen, DanZhang, Zhiweiنوع مدرک
TextOriginal Article
زبان مدرک
Englishچکیده
Objective(s): To explore the correlation between expression patterns and functions of miR-383 and LDHA in hepatocellular cancer (HCC). Materials and Methods: We detected the expression of miR-383 and LDHA in 30 HCC tissues and their matched adjacent normal tissues using qRT-PCR. Then we performed MTT assay, foci formation assay, transwell migration assay, glucose uptake assay and lactate production assay to explore the function of miR-383 in cell proliferation, invasion and glycolysis in HCC cell lines. Luciferase reporter assay was used to explore whether LDHA was a target gene of miR-383. Western blot and qRT-PCR were used to further confirm LDHA was targeted by miR-383. Then the above functional experiments were repeated to see whether the function of LDHA could be inhibited by miR-383. Results: The results of qRT-PCR showed that miR-383 was down-regulated in HCC tissues compared with their matched adjacent normal tissues. Functional experiments showed that overexpression of miR-383 significantly suppressed cell proliferation, invasion and glycolysis. Luciferase reporter assay showed LDHA was a target gene of miR-383 and expression of LDHA was inversely correlated with that of miR-383 in HCC. Besides, increased cell proliferation, invasion and glycolysis triggered by LDHA could be inhibited by overexpression of miR-383 in HCC cell lines. Conclusion: Our study proved that miR-383 is down-regulated in HCC and acts as a tumor suppressor through targeting LDHA. Targeting the miR-383-LDHA axis might be a promising strategy in HCC treatment.
کلید واژگان
Hepatocellular cancerLDHA
MiR-383
شماره نشریه
2تاریخ نشر
2017-02-011395-11-13
ناشر
Mashhad University of Medical Sciencesسازمان پدید آورنده
Department of Infectious Disease, XiangTan City Central Hospital, XiangTan, People's Republic of ChinaDepartment of Infectious Disease, XiangTan City Central Hospital, XiangTan, People's Republic of China
Department of Infectious Disease, XiangTan City Central Hospital, XiangTan, People's Republic of China
Department of Infectious Disease, XiangTan City Central Hospital, XiangTan, People's Republic of China
Edong Healthcare City Hospital of Traditional Chinese Medicine, Inefections Disease Hospital, Huangshi, People's Republic of China
Cancer Research Institute, University of South China, Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, Hengyang, People's Republic of China
شاپا
2008-38662008-3874




